This study is testing a treatment for a type of lung cancer called metastatic squamous non-small cell lung cancer (NSCLC). Metastatic means the cancer has spread to other parts of the body. The study compares two treatments: one with the drug pembrolizumab and another with pembrolizumab plus a new drug called sacituzumab tirumotecan (sac-TMT). The goal is to see if adding sac-TMT helps patients live longer. Patients will first receive four cycles of treatment every 3 weeks with pembrolizumab and other chemotherapy drugs. Then, they will be randomly assigned to continue with just pembrolizumab or pembrolizumab plus sac-TMT.

• Study Length: Participants will be monitored over several months.
• Visits Needed: Regular visits are required for treatment cycles and monitoring.
• Risks: Possible side effects include tiredness, nausea, and others typical of cancer treatments.

Participants must have a confirmed diagnosis of this lung cancer type and should not have other severe health issues. Those who have previously been treated with similar drugs may not qualify. If you meet the criteria, check with your doctor to see if this study might be right for you.